跳至主要内容
临床试验/NCT02083861
NCT02083861已完成不适用

ZetrOZ Wearable Ultrasound Clinical Study

ZetrOZ, Inc.2 个研究点 分布在 1 个国家目标入组 93 人开始时间: 2014年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
93
试验地点
2
主要终点
Pain on the Numeric Rating Scale (NRS) Change From Baseline to Study Conclusion

研究概览

简要总结

The purpose of this study is to measure the effectiveness of a wearable therapeutic ultrasound device in patients with stage I and stage II knee osteoarthritis. The ability of the device to reduce pain, increase mobility, increase range of motion and muscle strength of the affected leg, and improve quality of life in patients with knee osteoarthritis will be evaluated.

详细描述

This is an eight week study to clinically evaluate the effect of the low intensity long duration ultrasound (LITUS) device on symptoms of patients suffering from knee osteoarthritis. The device, sam® has been FDA-cleared for use. For the first two weeks of the study, baseline data will be collected as patients report pain scores (NRS) three times per day. During the following 6 weeks, patients will self-apply the wearable LITUS device to their affected knee for 4 hours daily. Each day of the study, pain scores (NRS) will be recorded immediately before application of LITUS device as well as 30 minutes, 2-hours and 4-hours after applying the device. A quality of life assessment (WOMAC), muscle strength and range of motion assessment (JTech) will be performed prior to the patient beginning the protocol and at the conclusion of the protocol.

Up to 93 subjects will be recruited from neighboring communities to the study site. The study is designed to reach a target patient population which includes rural citizens and socioeconomic disadvantaged individuals where non-pharmacotherapies do not exist to manage pain. Subjects will be randomly assigned to active (60%) and placebo groups (40%). The sponsor and investigators are blinded as to which type of device each patient is assigned.

The study will be monitored by an external monitor and a data safety monitoring board (DSMB).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
35 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Physician-diagnosed mild to moderate knee osteoarthritis (OARSI atlas grades 1-2) based on fixed-flexion x-ray radiological findings for osteophytes and joint space narrowing within the past 12 months
  • Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
  • 35-80 years of age
  • Report a frequent pain score between 3-7 (NRS range: 0-10) during the week preceding enrollment
  • Report that knee pain negatively affects quality of life
  • Willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study
  • Deemed appropriate by their physician or by the study site physician to participate

排除标准

  • Cannot successfully demonstrate the ability to put on and take off the device
  • Display any condition which, in the judgment of the investigator, would make participation in the study unacceptable, including, but not limited to, the subject's ability to understand and follow instructions.
  • Have severe OA or have little to no cartilage in the knee
  • Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months
  • Are non-ambulatory
  • Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening
  • Modify their medications during the course of the study (medications and doses must remain constant throughout the study)
  • Currently taking steroids
  • Have contraindication to radiograph
  • Have a secondary cause of arthritis (metabolic or inflammatory)

研究组 & 干预措施

Active ultrasound device

Experimental

Patients receive treatment from the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The active device emits continuous ultrasound at 3 megahertz (MHz) frequency and 0.132 watts/cm2 intensity.

干预措施: Sam Ultrasonic Diathermy Device (Device)

Placebo ultrasound device

Placebo Comparator

Patients wear the Sam Ultrasonic Diathermy Device for 4 hours every day for 6 weeks. The placebo device appears and operates identically to the active device except that it does not emit ultrasound.

干预措施: Sam Ultrasonic Diathermy Device (Device)

结局指标

主要结局

Pain on the Numeric Rating Scale (NRS) Change From Baseline to Study Conclusion

时间窗: Baseline, Week 6

The numeric rating scale (NRS) was used to assess change in pain from baseline to study conclusion. NRS range from 0-10 with 0 being no pain and 10 the worst pain possible.

次要结局

  • Muscle Strength Change From Baseline in Treated Knee(Baseline to 6 Weeks)
  • Quality of Life (WOMAC) Change From Baseline(Baseline, Week 6)
  • Range of Motion Change From Baseline in Treated Knee(Baseline, Week 6)

研究者

发起方
ZetrOZ, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验